Interpace Diagnostics Group Inc. | |
Stock Exchange | NASDAQ Stock Market |
EPS |
$0.41 |
Market Cap |
$27.05 M |
Shares Outstanding |
38.1 M |
Public Float |
37.41 M |
Address |
Morris Corporate Center 1 Parsippany New Jersey 07054 United States |
Employees | - |
Website | http://www.interpacediagnostics.com |
Updated | 07/08/2019 |
Interpace Diagnostics Group, Inc. is an bioinformatics company, which engages in the development and commercialization of molecular diagnostic test and pathology services. It offers PancraGEN, a pancreatic cyst and pancreaticobiliary solid lesion molecular test that can aid in pancreatic cyst diagnosis and pancreatic cancer risk assessment; ThyGenX and PathFinderTG which assesses thyroid nodules for risk of malignancy; and ThyraMIR, which assesses thyroid nodules for risk of malignancy utilizing a proprietary gene expression assay. The company was founded by John P. |